Pfizer to divest 100 products and cut 800 jobs worldwide

19 January 2009

Global drug behemoth Pfizer is to  sell off 100 products and cut 800 jobs worldwide as part of a major restructuring. The company will divest  a large number of compounds to rivals in a bid to turn defunct programs  into quick cash. Elsewhere, Pfizer is to cut 5% to 8% of its global  research staff by the end of this year. The lay-offs will include 240  jobs at the firm's plant in Kent, UK. The world's biggest drugmaker last  year reported it was to drastically reduce the product areas in which it  was operating (Marketletter October 6, 2008).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight